A Randomized Trial Using 3Mixtatin Compared to MTA in Primary Molars with Inflammatory Root Resorption: A Novel...

Area of Science:

• Pediatric Dentistry
• Endodontics
• Regenerative Medicine

Background:

• Preserving primary teeth is crucial for maintaining their development, aesthetics, and function.
• Bony defects from perforations in primary molars require effective repair methods.
• Mineral Trioxide Aggregate (MTA) is a common material for root repair, but novel alternatives are being explored.

Purpose of the Study:

• To compare the efficacy of a novel 3-antibiotic and simvastatin mixture (3Mixtatin) against MTA in repairing bony defects in primary molars with pre-treatment perforations.
• To evaluate the clinical and radiographic success rates of 3Mixtatin versus MTA in treating hopeless primary molars.

Main Methods:

• A randomized clinical trial involving 80 primary molars in 65 children (aged 3-6 years) with root resorption or perforation.
• Teeth were treated with either 3Mixtatin or MTA prior to conventional pulpectomy and restoration.
• Clinical and radiographic follow-ups were conducted at 4, 6, 12, and 24 months.

Main Results:

• After 24 months, 96.8% of teeth treated with 3Mixtatin showed no clinical signs/symptoms and arrested resorption.
• In contrast, 48.6% of teeth treated with MTA exhibited clinical issues (pain, mobility, sinus tract) and incomplete bone repair (18.9%).

Conclusions:

• 3Mixtatin treatment resulted in significantly higher rates of radiographic and clinical healing compared to MTA.
• This suggests 3Mixtatin may represent a paradigm shift in the endodontic treatment of primary teeth.
• Further research could validate 3Mixtatin as a superior alternative for preserving primary dentition.